Tag Archives: Emend

Heron Gains FDA Support For Nausea Drug After A Year Under Review

The decision that Heron Therapeutics has been waiting on for almost a year is finally in: The FDA has approved the Redwood City, CA-based company’s drug for nausea and vomiting associated with certain chemotherapy regimens. Heron (NASDAQ: HRTX) first submitted a new drug application for the treatment, granisetron (Sustol), to the FDA in September 2015. […]

Posted in National blog main, National top stories, San Francisco, San Francisco blog main, San Francisco top stories, Texas blog main | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on Heron Gains FDA Support For Nausea Drug After A Year Under Review

East Coast Biotech Roundup: X4, Rgenix, Alnylam, Intellia & More

What summer doldrums? It’s still not even Labor Day, yet the deals are already coming fast and furious. So fire up the grill and read on for some Series A rounds, crossover investments, data readouts, option-to-buy deals and more. —As Xconomy reported this week, a stealthy Cambridge, MA-based startup called X4 Pharmaceuticals raised a $37.5 […]

Posted in Boston, Boston blog main, National blog main, New York blog main, New York top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on East Coast Biotech Roundup: X4, Rgenix, Alnylam, Intellia & More

Tesaro Climbs on Phase 3 Data for Nausea Drug

Investors pummeled Tesaro in December when an anti-nausea drug it’s been developing for cancer patients missed some key secondary goals in the first two of three late-stage trials. But today the Waltham, MA-based company bounced back when it said a third trial came through unscathed. Tesaro (NASDAQ: TSRO) said today that rolapitant, a drug it’s […]

Posted in Boston, Boston blog main, National blog main | Tagged , , , , , , , , , , , , , , , , | Comments Off on Tesaro Climbs on Phase 3 Data for Nausea Drug

Investors Sink Tesaro Shares on Phase 3 Misses For Cancer Drug

Waltham, MA-based Tesaro (NASDAQ: TSRO) is trumpeting some late-stage success for its lead cancer drug, rolapitant, but investors clearly aren’t buying the results. Tesaro this morning released the top-line data from two Phase III trials for rolapitant, a drug it’s developing for chemotherapy-induced nausea and vomiting (CINV). The company emphasized that rolapitant hit the primary […]

Posted in Boston, Boston blog main, National blog main | Tagged , , , , , , , , , , , | Comments Off on Investors Sink Tesaro Shares on Phase 3 Misses For Cancer Drug